Sanofi Says US FDA Approves Subcutaneous Sarclisa for Multiple Myeloma

MT Newswires Live07-10

Sanofi (SNY) said Friday the US Food and Drug Administration has approved subcutaneous Sarclisa Escena combined with standard-of-care regimens to treat multiple myeloma across all existing indications for the intravenous formulation.

Sarclisa may now be delivered via both manual subcutaneous injection and the CirCLIQ on-body injector, the company said.

The approval was supported by the results of a pivotal phase 3 non-inferiority trial, which showed the subcutaneous formulation administered through an OBI matched the intravenous version in efficacy, pharmacokinetics and safety, while reducing treatment time and infusion-related reactions.

Sanofi said Sarclisa Escena is the first anticancer treatment approved for administration through an on-body injector in the US.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment